scholarly journals The aging male population and medical care for benign prostatic hyperplasia in Canada

2010 ◽  
Vol 4 (2) ◽  
pp. 123-127 ◽  
Author(s):  
Nigel S. B. Rawson ◽  
Fred Saad
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Medical Care ◽  
Prostatic Hyperplasia ◽  
Aging Male ◽  
Male Population

scholarly journals The aging male population and medical care for benign prostatic hyperplasia in Canada

2013 ◽  
Vol 4 (2) ◽  
pp. 123
Author(s):  
Nigel S. B. Rawson ◽  
Fred Saad
Keyword(s):  
Primary Care ◽  
Benign Prostatic Hyperplasia ◽  
Nous Avons ◽  
Medical Care ◽  
Primary Care Physicians ◽  
Prostatic Hyperplasia ◽  
Population Projections ◽  
Prise En Charge ◽  
Male Population ◽  
Statistics Canada

Background: The male Canadian population is aging and more menwill be seeking medical care for benign prostatic hyperplasia (BPH).We examined the projected increase in older Canadian males between2005 and 2018 to evaluate urologic health-care needs.Methods: We used Statistics Canada population projections toderive predictions of the male population aged 50 or more from2005 to 2018 and results from the Olmsted County Study of UrinarySymptoms to estimate numbers of males aged ≥50 with moderateto severe lower urinary tract symptoms (msLUTS) in the sameperiod. Data from the Canadian Institute for Health Informationwere used to estimate the number of urologists in 2018.Results: The number of Canadian men aged ≥50 is projected torise between 2005 and 2018 by 39.5% and the number withmsLUTS by 41.3%. However, the number of practicing urologistsin Canada in 2018 is likely to be similar to the 584 practicing in2007. An increase in the number of urologists proportional to theincrease in men aged ≥50 with msLUTS would require 799 urologistsin 2018.Interpretation: Little opportunity exists to expand the number of traineesin urology. Other alternatives must be sought to deal with increasednumbers of older men with msLUTS. Initial management of BPHhas moved towards being a responsibility of primary care physicians,but they appear to view BPH as a quality-of-life issue. It iscrucial that urologists work closely with primary care physicians toensure that the management of LUTS progression is optimized.Introduction : La population masculine canadienne vieillit, et deplus en plus d’hommes consulteront un médecin en raison d’unehyperplasie bénigne de la prostate (HBP). Nous avons étudié levieillissement prévu de cette population entre 2005 et 2018 afind’évaluer les besoins en soins urologiques.Méthodologie : À l’aide des projections démographiques de StatistiqueCanada, nous avons formulé des prévisions quant à la populationmasculine de 50 ans et plus entre 2005 et 2018; les résultatsde l’étude du comté d’Olmsted sur les symptômes urinaires nousont permis d’évaluer le nombre d’hommes de 50 ans et plus quidevraient présenter des symptômes modérés ou graves touchantles voies urinaires inférieures pendant la même période. Desdonnées de l’Institut canadien d’information sur la santé ont permisd’évaluer le nombre d’urologues en 2018.Résultats : Le nombre de Canadiens de 50 ans et plus devrait augmenterde 39,5 % entre 2005 et 2018, et le nombre d’hommesprésentant des symptômes modérés ou graves touchant les voiesurinaires inférieures, de 41,3 %. En revanche, le nombre d’urologuespratiquant en 2018 au Canada devrait être semblable aunombre établi en 2007 (soit 584). Pour que la hausse du nombred’urologues soit proportionnelle à la hausse du nombre d’hommesde 50 ans et plus qui présenteront des symptômes modérés ougraves touchant les voies urinaires inférieures, il faudrait que cenombre atteigne 799 en 2018.Conclusion : Il est peu probable que le nombre de médecins sespécialisant en urologie augmente. D’autres solutions doiventdonc être mises de l’avant afin de faire face au nombre croissantd’hommes âgés au prise avec des symptômes modérés ou gravestouchant les voies urinaires inférieures. La prise en charge initialede l’HBP incombe maintenant aux médecins de premiersrecours, mais ces derniers semblent considérer l’HBP comme unproblème de qualité de vie. Il est primordial que les urologuescollaborent étroitement avec les médecins de soins primaires pourassurer une prise en charge optimale des symptômes touchantles voies urinaires inférieures.

Prevention system and medical support for patients with benign prostatic hyperplasia

2021 ◽  
pp. 18-27
Author(s):  
Egor Aleksandrovich Perevezentsev ◽  
Nadezhda Ilyinichna Gurvich ◽  
Tatyana Andreevna Agapova
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Support System ◽  
Primary Care Physicians ◽  
Prostatic Hyperplasia ◽  
Weak Continuity ◽  
Medical Support ◽  
Male Population ◽  
Minimally Invasive Surgical ◽  
Surgical Methods ◽  
High Level

The article presents an analysis of the current state of the prevention and medical support system for patients with benign prostatic hyperplasia. The urgency of the problem is determined by the significant influence of benign prostatic hyperplasia (BPH) on the quality of life of the male population. The identified shortcomings of the prevention and medical support system (low rates of referral and awareness of the population, insufficiently high level of urological training of primary care physicians, weak continuity between outpatient clinics, etc.) indicate the need for changes in the system of urological care for patients with BPH. The combined use of effective preventive measures and minimally invasive surgical methods for treating BPH increases the efficiency of outpatient and inpatient institutions.

scholarly journals Anti-Inflammatory and Antioxidant Effects of Kelong-Capsule on Testosterone-Induced Benign Prostatic Hyperplasia in Rats

2018 ◽  
Vol 2018 ◽  
pp. 1-8
Author(s):  
Ling Zhang ◽  
Xin-Rong Fan ◽  
Hui Xie ◽  
Qing-Hu He ◽  
Yu-Song Nie ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Common Disease ◽  
Related Factor ◽  
Group Model ◽  
Model Group ◽  
Male Population ◽  
Treatment Groups ◽  
Ageing Male ◽  
Antioxidant Effects

Benign prostatic hyperplasia (BPH) is a common disease in the current ageing male population. This research aims to study the effects of Kelong-Capsules (KLC) on testosterone-induced BPH. Thirty rats were randomly divided into normal group, model group, and three treatment groups. Three treatment groups were given KLC (3.6 g/kg), KLC (7.2 g/kg), and finasteride (0.9 mg/kg), respectively, for 28 days after establishing the animal model. The BPH rat models were evaluated by Traditional Chinese Medicine (TCM) symptoms and prostate index (PI). Results indicated that three treatment groups all alleviated the pathological changes of prostate and kidney at different levels. Compared with the model group, the PI of the groups treated with KLC (7.2 g/kg) and finasteride decreased significantly. The expressions of NF-E2 related factor 2 (Nrf-2) and quinine oxidoreductase (NQO1) in the group treated with KLC (3.6 g/kg) increased markedly (p<0.01). The cyclooxygenase-2 (COX-2) protein expression of the group treated with KLC (7.2 g/kg) was increased (p<0.01). In conclusion, KLC could obviously inhibit the growth of prostate, and KLC (3.6 g/kg) could promote the expressions of Nrf2 and NQO1.

scholarly journals Use of tamsulosin and dutasteride combination for the management of benign prostatic hyperplasia: a real world practice survey (VELTAM survey)

2021 ◽  
Vol 8 (8) ◽  
pp. 1183
Author(s):  
Sudip Sarkar
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Clinical Experience ◽  
Real World ◽  
Gold Standard ◽  
Prostatic Hyperplasia ◽  
First Line ◽  
Male Population ◽  
Practice Survey ◽  
Co Morbidity ◽  
High Prevalence

Background: Benign prostatic hyperplasia has high prevalence ranging from 8-80% affecting male population. Dutasteride and tamsulosin combination has been found to be more effective as compared to individual monotherapy. However, evidence on real world clinical experience on this combination is lacking. Aim and Objective of current study was to gather the evidence on real world clinical experience from the physicians using the combination of tamsulosin and dutasteride for the management of BPH.Methods: Responses from 1571 physicians who were the current prescribers of tamsulosin with dutasteride combination for the management of BPH were collected in a questioner containing a set of nine questions having multiple choice answers. All the data is expressed as number and percentage.Results: Majority of the physicians considered tamsulosin with dutasteride combination as the gold standard therapy for the treatment of BPH (88.86%). Most common co-morbidities which physician takes in to consideration was cardiovascular (62.61%) followed by asthma (23.04%). While treating BPH patients with cardiovascular co-morbidities, majority of the physician consider drug-drug interaction as significant criteria to decide the therapy (87.83%).Conclusions: Physicians considered tamsulosin and dutasteride combination as the gold standard for the management of BPH with cardiovascular co-morbidity. Tamsulosin and dutasteride combination is the first line choice for the management of BPH in real world practice. 

Report on: “Benign Prostatic Hypertrophy (BPH): Diagnostic and Therapeutic Problems” - Introduction

1994 ◽  
Vol 61 (3) ◽  
pp. 167-168
Author(s):  
G. Fiaccavento
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Clinical Manifestation ◽  
Therapeutic Approach ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hyperplasia ◽  
Prostatic Hypertrophy ◽  
Male Population ◽  
Pathological Lesions

Benign prostatic hyperplasia (BPH) is widespread among the male population and its frequency increases with age. Anatomo-pathological lesions do not always correspond to clinical manifestation of the disease. Some of the most controversial points in the diagnostic and therapeutic approach are discussed.

Sign in / Sign up

Export Citation Format

Share Document